Specifically, HCC cells with TP53 loss-of-function mutations upregulate PD-L1 expression through activation of the mTORC1 pathway, whereas HCC with wild-type TP53 increases PD-L1 expression via mTORC1 inhibition. Here, TP53 is linked to hepatocellular carcinoma.